Table 2.
Baseline pulmonary function parameters and maintenance medications of patients with COPD from the KOCOSS according to the presence of chronic bronchitis and BMI categories
| Total (N = 1264) | Non-CB | CB | P | |||
|---|---|---|---|---|---|---|
| BMI ≥ 25 (n = 230) | BMI < 25 (n = 583) | BMI ≥ 25 (n = 98) | BMI < 25 (n = 353) | |||
| Pulmonary function | ||||||
| Post bronchodilator FVC, L | 3.16 ± 0.82 | 3.14 ± 0.84 | 3.12 ± 0.82 | 3.35 ± 0.74 | 3.20 ± 0.82 | 0.046 |
| Post bronchodilator FVC, % pred (N = 1262) | 84.1 ± 18.6 | 82.4 ± 18.9 | 83.7 ± 17.8 | 84.3 ± 15.1 | 85.6 ± 20.4 | 0.203 |
| Post bronchodilator FEV1, L | 1.61 ± 0.57 | 1.76 ± 0.56 | 1.57 ± 0.58 | 1.82 ± 0.52 | 1.51 ± 0.53 | < 0.0001 |
| Post bronchodilator FEV1, % pred (N = 1262) | 60.8 ± 19.6 | 66.2 ± 18.8 | 60.1 ± 20.0 | 65.4 ± 15.9 | 57.1 ± 19.4 | < 0.0001 |
| ≥ 80% pred | 181 (14.3) | 46 (20.0) | 83 (14.3) | 16 (16.5) | 36 (10.2) | < 0.0001 |
| 50% pred ≤ FEV1 < 80% pred | 704 (55.8) | 146 (63.5) | 302 (51.9) | 68 (70.1) | 188 (53.3) | |
| < 50% pred | 377 (29.9) | 38 (16.5) | 197 (33.8) | 13 (13.4) | 129 (36.5) | |
| Post bronchodilator FEV1/FVC | 0.51 ± 0.13 | 0.56 ± 0.11 | 0.51 ± 0.14 | 0.54 ± 0.11 | 0.47 ± 0.12 | < 0.0001 |
| Bronchodilator responsea | 96 (7.6) | 16 (7.0) | 32 (5.5) | 10 (10.2) | 38 (10.8) | 0.020 |
| Diffusing capacity, % pred (N = 970) | 75.3 ± 23.8 | 82.3 ± 21.2 | 76.1 ± 25.3 | 79.2 ± 21.9 | 68.4 ± 21.7 | < 0.0001 |
| < 60% pred | 240 (24.7) | 20 (11.3) | 114 (26.0) | 14 (17.3) | 92 (33.6) | < 0.0001 |
| RV/TLC, % (N = 754) | 45.0 ± 12.8 | 43.5 ± 11.5 | 46.2 ± 13.82 | 40.4 ± 12.4 | 45.4 ± 11.8 | 0.005 |
| 6MWD, m (N = 1003) | 374.8 ± 116.5 | 379.9 ± 110.5 | 379.8 ± 118.9 | 388.8 ± 106.9 | 360.0 ± 118.0 | 0.071 |
| Baseline medication | ||||||
| No | 116(9.2) | 27(11.7) | 56(9.6) | 7(7.1) | 26(7.4) | 0.282 |
| Yes | 1148(90.8) | 203(88.3) | 527(90.4) | 91(92.9) | 327(92.6) | |
| LAMA (N = 1124) | 744 (66.2) | 124 (61.7) | 334 (64.0) | 56 (66.7) | 230 (72.6) | 0.034 |
| LABA (N = 1063) | 207 (19.5) | 31 (16.4) | 96 (19.5) | 16 (20.5) | 64 (21.1) | 0.633 |
| ICS + LABA (N = 1082) | 504 (46.6) | 77 (38.7) | 229 (45.9) | 39 (52.0) | 159 (51.5) | 0.031 |
| ICS + LABA + LAMA (N = 1058) | 395 (37.3) | 56 (29.3) | 191 (39.1) | 20 (28.2) | 128 (41.7) | 0.012 |
| PDE-4 inhibitor (N = 1022) | 57(5.6) | 7(3.8) | 23(4.9) | 1(1.4) | 26(8.7) | 0.023 |
Data are presented as mean ± standard deviation or number (%). P values < 0.05 are presented in bold
BMI, body mass index; CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; KOCOSS, Korean COPD Subgroup Study; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; PDE-4 inhibitor, phosphodiesterase-4 inhibitor; RV, residual volume; TLC, total lung capacity; 6MWD, 6-min walk distance
aPositive bronchodilator response was defined as the post-bronchodilator increase in FEV1 or FVC of at least 12% and 200 mL from baseline values at 15 min after inhalation of 400 μg of salbutamol